Recurrent aphthosic stomatitis: rebamipide – a new direction in treatment and prevention

Dmitry I. Trukhan , Anatoly F. Sulimov , Larisa Yu. Trukhan

For citation:

Abstract

Recurrent aphthous stomatitis (RAS) is a widespread disease worldwide, accompanied by the appearance of painful aphthae on the oral mucosa. RAS is a multifactorial disease. Local and systemic factors such as trauma, food sensitivities, nutritional deficiencies, systemic conditions, immunological disorders and genetic polymorphisms are associated with its development. Studies examining the possible connection between the development of RAS and Helicobacter pylori infection are reviewed. The review examined publications on the use of the universal gastro- and enteroprotector rebamipide as a new direction in the treatment and prevention of RAS. Clinical data clearly establish the safety and effectiveness of rebamipide in the treatment of RAS and Behçet's disease. The benefits of rebamipide for RAS include: reduced pain duration, accelerated healing and reduced relapse rates. Aphthous stomatitis (oral mucositis) can be induced by chemotherapy and radiation therapy in oncology practice, with an incidence reaching 100% in patients receiving high-dose chemotherapy and up to 80% of patients receiving radiation therapy. A number of studies in its treatment and prevention have also demonstrated the effectiveness and safety of systemic and local use of rebamipide. The presented review expands the scope of rebamipide, suggesting the possibility of its use in dental and oncological practice for the treatment and prevention of RAS, including Behcet's disease, and oral mucositis.
Keywords: recurrent aphthous stomatitis, Behcet's disease, oral mucositis, rebamipide, treatment, prevention, oncology, dentistry.

References

1. Cheng YO, Veettil SK, Syeed MS, Shetty NY, Gopinath D. Comparative efficacy of therapeutic interventions for the management of recurrent aphthous ulcers: a systematic review and network meta-analysis. J Evid Based Dent Pract. 2023;23(4):101918. DOI: 10.1016/j.jebdp.2023. 101918

2. Волков Е.А., Бутова В.Г., Позднякова Т.И., Дзугаева И.И. Клинические рекомендации (протокол лечения) хронический рецидивирующий афтозный стоматит. Российский стоматологический журнал. 2014;5: 35-49. https://www.elibrary.ru/item.asp?id=22512498

Volkov E.A., Butova V.G., Pozdnyakova T.I., Dzugaeva I.I. Klinicheskie rekomendacii (protokol lecheniya) xronicheskij recidiviruyushhij aftozny`j stomatit. Rossijskij stomatologicheskij zhurnal. 2014;5: 35-49. https://www.elibrary.ru/item.asp?id=22512498 (in Russian).

3. Gomes CC, Gomez RS, Zina LG, Amaral FR. Recurrent aphthous stomatitis and Helicobacter pylori. Med Oral Patol Oral Cir Bucal. 2016;21(2):e187-91. DOI: 10.4317/medoral.20872

4. Li L, Gu H, Zhang G. Association between recurrent aphthous stomatitis and Helicobacter pylori infection: a meta-analysis. Clin Oral Investig. 2014;18(6):1553-60. DOI: 10.1007/s00784-014-1230-5

5. Adler I, Muiño A, Aguas S et al. Helicobacter pylori and oral pathology: relationship with the gastric infection. World J Gastroenterol. 2014;20(29):9922-35. DOI: 10.3748/wjg.v20.i29.9922

6. Gülseren D, Karaduman A, Kutsal D, Nohutcu RM. The relationship between recurrent aphthous stomatitis, and periodontal disease and Helicobacter Pylori infection. Clin Oral Investig. 2016;20(8):2055-60. DOI: 10.1007/s00784-015-1704-0

7. Karaca S, Seyhan M, Senol M, Harputluoglu MM, Ozcan A. The effect of gastric Helicobacter pylori eradication on recurrent aphthous stomatitis. Int J Dermatol. 2008;47(6):615-7. DOI: 10.1111/j.1365-4632.2008.03667.x

8. Gao Y, Gupta N, Abdalla M. Recurrent Aphthous Stomatitis Improved after Eradication Therapy for Helicobacter pylori. Case Rep Gastrointest Med. 2021;2021:5543838. DOI: 10.1155/2021/5543838

9. Albanidou-Farmaki E, Giannoulis L, Markopoulos A et al. Outcome following treatment for Helicobacter pylori in patients with recurrent aphthous stomatitis. Oral Dis. 2005;11(1):22-6. DOI: 10.1111/j.1601-0825.2004.01053.x

10. Taş DA, Yakar T, Sakalli H, Serin E. Impact of Helicobacter pylori on the clinical course of recurrent aphthous stomatitis. J Oral Pathol Med. 2013;42(1):89-94. DOI: 10.1111/j.1600-0714.2012.01197.x

11. Shen J, Ye Z, Xie H et al. The relationship between Helicobacter pylori infection and recurrent aphthous stomatitis: a systematic review and meta-analysis. Clin Oral Investig. 2023 Nov;27(11):6345-56. DOI: 10.1007/s00784-023-05273-y

12. Bhargava S, Dubey SP, Haldipur D et al. Management of Recurrent Aphthous Stomatitis: An Indian Expert Consensus. Indian J Otolaryngol Head Neck Surg. 2023;75(3):2672-80. DOI: 10.1007/s12070-023-03708-2

13. Matysiak-Budnik T, Heyman M, Megraud F. Review article: rebamipide and the digestive epithelial barrier. Aliment Pharmacol Ther. 2003;18 (Suppl. 1):55-62. DOI: 10.1046/j.1365-2036.18.s1.6.x

14. Arakawa T, Higuchi K, Fujiwara Y et al. 15th anniversary of rebamipide: looking ahead to the new mechanisms and new applications. Dig Dis Sci. 2005;50 (Suppl. 1):S3-S11. DOI: 10.1007/s10620-005-2800-9

15. Fujiwara Y, Higuchi K, Tominaga K et al. Quality of ulcer healing and rebamipide. 2005;63 (Suppl. 11):397-400. Available at: https://www. ncbi.nlm.nih.gov/pubmed/16363567

16. Naito Y, Yoshikawa T. Rebamipide: a gastrointestinal protective drug with pleiotropic activities. Expert Rev Gastroenterol Hepatol. 2010;4(3):261-70. DOI: 10.1586/ egh.10.25

17. Zhang S, Qing Q, Bai Y et al. Rebamipide helps defend against nonsteroidal anti-inflammatory drugs induced gastroenteropathy: a systematic review and meta-analysis. Dig Dis Sci. 2013;58(7):1991-2000. DOI: 10.1007/s10620-013-2606-0

18. Симаненков В.И., Маев И.В., Ткачева О.Н. и др. Синдром повышенной эпителиальной проницаемости в клинической практике. Мультидисциплинарный национальный консенсус. Кардиоваскулярная терапия и профилактика. 2021;20(1):2758. DOI: 10.15829/1728-8800-2021-2758

Simanenkov V.I., Maev I.V., Tkacheva O.N. et al. Syndrome of increased epithelial permeability in clinical practice. Multidisciplinary national Consensus. Cardiovascular Therapy and Prevention. 2021;20(1):2758. DOI: 10.15829/1728-8800-2021-2758 (in Russian).

19. Suetsugu H, Ishihara S, Moriyama N et al. Effect of rebamipide on prostaglandin EP4 receptor gene expression in rat gastric mucosa. J Lab Clin Med. 2000;136(1):50-7. DOI: 10.1067/mlc.2000.107303

20. Fujioka T, Arakawa T, Shimoyama T et al. Effects of rebamipide, a gastro-protective drug on the Helicobacter pylori status and inflammation in the gastric mucosa of patients with gastric ulcer: a randomized double-blind placebo-controlled multicentre trial. Aliment Pharmacol Ther. 2003;18 (Suppl 1):146-52. DOI: 10.1046/j.1365-2036.18.s1.20.x

21. Kleine A, Kluge S, Peskar BM. Stimulation of prostaglandin biosynthesis mediates gastroprotective effect of rebamipide in rats. Dig Dis Sci. 1993;38(8):1441-9. DOI: 10.1007/bf01308601

22. Sun WH, Tsuji S, Tsujii M et al. Induction of cyclooxygenase-2 in rat gastric mucosa by rebamipide, a mucoprotective agent. J Pharmacol Exp Ther. 2000;295(2):447-52. URL: https://www.ncbi.nlm.nih.gov/ pubmed/11046075

23. Yoshida N, Yoshikawa T, Iinuma S et al. Rebamipide protects against activation of neutrophils by Helicobacter pylori. Dig Dis Sci. 1996;41(6):1139-44. DOI: 10.1007/bf02088229

24. Arakawa T, Kobayashi K, Yoshikawa T. Rebamipide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing. Dig Dis Sci. 1998;43(9):5-13.

25. Du Y, Li Z, Zhan X et al. Anti-inflammatory effects of rebamipide according to Helicobacter pylori status in patients with chronic erosive gastritis: a randomized sucralfate-controlled multicenter trial in China-STARS study. Dig Dis Sci. 2008;53(11):2886-95. DOI: 10.1007/ s10620-007-0180-z

26. Masamune A, Yoshida M, Sakai Y, Shimosegawa T. Rebamipide inhibits ceramide-induced interleukin-8 production in Kato III human gastric cancer cells. J Pharmacol Exp Ther. 2001;298(2):485-92. URL: https://www.ncbi.nlm.nih.gov/pubmed/11454909

27. Sugimoto M, Uotani T, Furuta T. Does rebamipide prevent gastric mucosal injury in patients taking aspirin and clopidogrel? Dig Dis Sci. 2014;59(8):1671-3. DOI: 10.1007/s10620-014-3145-z

28. Suzuki T, Yoshida N, Nakabe N et al. Prophylactic effect of rebamipide on aspirin-induced gastric lesions and disruption of tight junctional protein zonula occludens-1 distribution. J Pharmacol Sci. 2008;106(3):469-77. DOI: 10.1254/jphs. FP0071422

29. Mizukami K, Murakami K, Abe T et al. Aspirin-induced small bowel injuries and the preventive effect of rebamipide. World J Gastroenterol. 2011;17(46):5117-22. DOI: 10.3748/wjg.v17.i46.5117

30. Nishizawa T, Suzuki H, Nakagawa I et al. Rebamipide-promoted restoration of gastric mucosal sonic hedgehog expression after early Helicobacter pylori eradication. Digestion. 2009;79(4):259-62. DOI: 10.1159/000213241.

31. Tarnawski AS, Jones MK. The role of epidermal growth factor (EGF) and its receptor in mucosal protection, adaptation to injury, and ulcer healing: involvement of EGF-R signal transduction pathways. J Clin Gastroenterol. 1998;27 (Suppl 1):S12-20. DOI: 10.1097/00004836-199800001-00004

32. Tarnawski AS, Chai J, Pai R, Chiou SK. Rebamipide activates genes encoding angiogenic growth factors and Cox2 and stimulates angiogenesis: a key to its ulcer healing action? Dig Dis Sci. 2004;49(2):202-9. DOI: 10.1023/b:ddas.0000017439.60943.5c

33. Udagawa A, Shiota G, Ichiba M, Murawaki Y. Effect of rebamipide on acetic acid-induced gastric ulcer in rats: involvement of hepatocyte growth factor. Scand J Gastroenterol. 2003;38(2):141-6. DOI: 10.1080/00365520310000609

34. Watanabe S, Wang XE, Hirose M et al. Effects of rebamipide on bile acid-induced inhibition of gastric epithelial repair in a rabbit cell culture model. Aliment Pharmacol Ther. 1996;10(6):927-32. DOI: 10.1046/j.1365-2036.1996.105276000.x

35. Hahm KB, Park IS, Kim YS et al. Role of rebamipide on induction of heat-shock proteins and protection against reactive oxygen metabolite-mediated cell damage in cultured gastric mucosal cells. Free Radic Biol Med. 1997;22(4):711-6. DOI: 10.1016/s0891-5849(96)00406-6

36. Masanobu T, Tomoya T, Asano R et al. Rebamipide suppresses 5-fluorouracil-induced cell death via the activation of Akt/mTOR pathway and regulates the expression of Bcl-2 family proteins. Toxicology in Vitro. 2018;46:284-93. DOI: 10.1016/j.tiv.2017.10.019

37. Rao JN, Guo X, Liu L et al. Polyamines regulate Rho-kinase and myosin phosphorylation during intestinal epithelial restitution. Am J Physiol Cell Physiol. 2003;284:848-59. DOI: 10.1152/ ajpcell.00371.2002

38. Takagi T, Naito Y, Uchiyama K et al. Rebamipide promotes healing of colonic ulceration through enhanced epithelial restitution. World J Gastroenterol. 2011;17(33):3802-9. DOI: 10.3748/wjg.v17.i33.3802

39. Suzuki H, Mori M, Kai A et al. Effect of rebamipide on H. pylori-associated gastric mucosal injury in Mongolian gerbils. Dig Dis Sci. 1998;43 (9 Suppl):181S-187S. URL: https://www.ncbi.nlm.nih.gov/pubmed/ 9753247

40. Hayashi S, Sugiyama T, Amano K et al. Effect of rebamipide, a novel antiulcer agent, on Helicobacter pylori adhesion to gastric epithelial cells. Antimicrob Agents Chemother. 1998;42(8):1895-9. URL: https:// www.ncbi.nlm.nih.gov/pmc/articles/PMC105706/

41. Meghanadh KR, Kaur M, Haldipur D et al. Rebamipide in Recurrent Aphthous Stomatitis: review of indian evidence. The Indian Practitioner. 2021;74:30-5. URL: https://www.wosonhj.com/scholar/367091xs.html

42. Jadhav A, Marathe S, Mhapuskar A, Jadhav S. To evaluate the efficacy of rebamipide on clinical resolution and recurrence of minor recurrent aphthous stomatitis. Int J Dent Health Sci. 2015;2:781-797. URL: https://www.researchgate.net/publication/299617275_TO_EVALUATE_THE_EFFICACY_OF_REBAMIPIDE_ON_CLINICAL_RESOLUTION_AND_RECURRENCE_OF_MINOR_RECURRENT_APHTHOUS_STOMATITIS

43. Hasan S, Perween N, Saeed S, Kaur M, Gombra V, Rai A. Evaluation of 5% Amlexenox Oral Paste and Rebamipide Tablets in Treatment of Recurrent Apthous Stomatitis and Comparison with Dologel CT. Indian J Otolaryngol Head Neck Surg. 2022;74(Suppl 3):5228-34. DOI: 10.1007/s12070-020-01858-1

44. Uppalwar P, Kunjir G, Krishna Kumar R et al. Comparison of therapeutic effect of topical Amlexanox (5%), and oral Rebamipide (100 mg) in the management of oral aphthous ulceration. J Oral Dent Health. 2016;2:6–8. URL: https://scholar.google.com/scholar?hl=ru&as_ sdt=0%2C5&q=Comparison+of+therapeutic+effect+of+topical+Amlexanox+%285%25%29%2C+and+oral+Rebamipide+%28100+mg%29+in+the+management+of+oral+aphthous+ulceration&btnG=

45. Hasan S, Mohd. Faisal Siddique. Management of major recurrent aphthous ulcers with 5% amlexanox oral paste and rebamipide tablets- A case report with a brief literature review. IP Int J Periodontol Implantol. 2023;8(4):225-9. DOI: 10.18231/j.ijpi.2023.043

46. Parvathi Devi MK, Ramesh DN, Koppal S et al. Efficacy of rebamipide and levamisole in the treatment of patients with recurrent aphthous ulcer – a comparative study. J Clin Diagn Res. 2014;8(11):ZC119-22. DOI: 10.7860/JCDR/2014/10295.5202

47. Kudur MH, Hulmani M. Rebamipide: A Novel Agent in the Treatment of Recurrent Aphthous Ulcer and Behcet's Syndrome. Indian J Dermatol. 2013;58(5):352-4. DOI: 10.4103/0019-5154.117298

48. Taylor J, Glenny AM, Walsh T et al. Interventions for the management of oral ulcers in Behçet's disease. Cochrane Database Syst Rev. 2014;2014(9):CD011018. DOI: 10.1002/14651858.CD011018.pub2

49. Lau CB, Smith GP. Recurrent aphthous stomatitis: A comprehensive review and recommendations on therapeutic options. Dermatol Ther. 2022;35(6):e15500. DOI: 10.1111/dth.15500

50. Matsuda T, Ohno S, Hirohata S et al. Efficacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with Behçet's disease: a randomised, double-blind, placebo-controlled study. Drugs R D. 2003;4(1):19-28. DOI: 10.2165/00126839-200304010-00002

51. Kawano Y, Hanawa T. Development of Hospital Formulations Based on Medical Need. Yakugaku Zasshi. 2019;139(10):1275-80. DOI: 10.1248/yakushi.19-00121-2

52. Enami A, Masuda N, Yamamura J, et al. Therapeutic effect of rebamipide for oral mucositis associated with FEC therapy for breast cancer. Gan To Kagaku Ryoho. 2014;41(11):1407-12. URL: https://pubmed. ncbi.nlm.nih.gov/25434444/

53. Ishii N, Mizobuchi S, Kawano Y, Hanawa T. Preparation and Evaluation of a Powdered Rebamipide Mouthwash as In-Hospital Formulation: Considering Dispersion before Use in Patients. Pharmaceutics. 2021;13(11):1848. DOI: 10.3390/pharmaceutics13111848

54. Nakashima T, Sako N, Matsuda T, Uematsu N et al. Novel submicronized rebamipide liquid with moderate viscosity: significant effects on oral mucositis in animal models. Biol Pharm Bull. 2014;37(4):671-8. DOI: 10.1248/bpb.b13-01006

55. Nakashima T, Uematsu N, Sakurai K. Intra-oral administration of rebamipide liquid prevents tongue injuries induced by X-ray irradiation in rats. Support Care Cancer. 2017;25(7):2205-13. DOI: 10.1007/ s00520-017-3626-7

56. Yasuda T, Chiba H, Satomi T et al. A pilot study of rebamipide-gargle for chemoradiotherapy-induced mucositis in oral cancer patient. Gan To Kagaku Ryoho. 2008;35(7):1157-61. URL: https://pubmed.ncbi. nlm.nih.gov/18633254/

57. Kabeya M, Ina K, Yuasa S et al. Pilot study on clinical effects of rebamipide gargle against oral mucositis induced by fluoropyrimidines. Gan To Kagaku Ryoho. 2011l;38(7):1133-6. URL: https://pubmed. ncbi. nlm.nih.gov/21772097/

58. Ishii N, Kawano Y, Sakai H et al. Effects of a Rebamipide Mouthwash on Stomatitis Caused by Cancer Chemotherapy-Evaluation of the Efficacy by Patients Themselves. Yakugaku Zasshi. 2017;137(8):1027-34. DOI: 10.1248/yakushi.17-00042

59. Takeuchi I, Togo C, Makino K. Rebamipide-containing Film Using Chitosan and HPMC for Oral Mucositis Induced by Cancer Chemotherapy. Anticancer Res. 2019;39(12):6531-36. DOI: 10.21873/anticanres. 13868

60. Shinohara A, Nakamura M, Onikubo T, Nakamura K. Efficacy of Rebamipide Gargle against Chemotherapy-induced Oral Mucositis. Yakugaku Zasshi. 2015;135(8):937-41. DOI: 10.1248/yakushi.15-00112-2

61. Chaitanya B, Pai KM, Yathiraj PH et al. Rebamipide gargle in preventive management of chemo-radiotherapy induced oral mucositis.

Oral Oncol. 2017;72:179-82. DOI: 10.1016/j.oraloncology.2017.

07.024

62. Yokota T, Ogawa T, Takahashi S et al. Efficacy and safety of rebamipide liquid for chemoradiotherapy-induced oral mucositis in patients with head and neck cancer: a multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II study. BMC Cancer. 2017;17(1):314. DOI: 10.1186/s12885-017-3295-4

63. Akagi S, Fujiwara T, Nishida M et al. The effectiveness of rebamipide mouthwash therapy for radiotherapy and chemoradiotherapy-induced oral mucositis in patients with head and neck cancer: a systematic review and meta-analysis. J Pharm Health Care Sci. 2019;5:16. DOI: 10.1186/s40780-019-0146-2

64. Трухан Д.И., Иванова Д.С. Лекарственная безопасность в реальной клинической практике: акцент на протекторную терапию. Фарматека. 2022; 29(3):72-82. DOI: 10.18565/pharmateca.2022.3.72-82

Trukhan D.I., Ivanova D.S. Drug safety in real clinical practice: focus on protective therapy. Farmateka. 2022;29(3):72-82. DOI: 10.18565/ pharmateca.2022.3.72-8 (in Russian).

For citation:Trukhan D.I., Sulimov A.F., Trukhan L.Yu. Recurrent aphthosic stomatitis: rebamipide – a new direction in treatment and prevention. Clinical review for general practice. 2024; 5 (1): 23–29 (In Russ.). DOI: 10.47407/kr2023.5.1.00355

All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

Clinical review for general practice